Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21856683 | 0.82 | AXL (0.40) | AXLNOS1METAP2CSNK2A1DYRK1A | |
| SCHEMBL22655739 | 0.79 | AXL (0.36) | AXLNOS1METAP2CSNK2A1DYRK1A | |
| SCHEMBL29266690 | 0.79 | AXL (0.40) | AXLNOS1METAP2CSNK2A1DYRK1A | |
| SCHEMBL21901866 | 0.77 | CDC7 (0.40) | — | |
| SCHEMBL21856805 | 0.68 | AXL (0.49) | AXLNOS1METAP2CSNK2A1DYRK1A | |
| SCHEMBL21901264 | 0.68 | AXL (0.43) | AXLNOS1METAP2CSNK2A1DYRK1A | |
| SCHEMBL21900957 | 0.68 | PGK1 (0.38) | NOS1CSNK2A1DYRK1ACHEK1TRPA1 | |
| SCHEMBL22655895 | 0.66 | AXL (0.54) | AXLNOS1METAP2CSNK2A1DYRK1A | |
| SCHEMBL22768431 | 0.66 | AXL (0.41) | AXLNOS1METAP2CSNK2A1DYRK1A | |
| SCHEMBL23887929 | 0.64 | PGK1 (0.33) | NOS1DYRK1ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2020081257-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | AXL 4839/4885NOS1 1042/4885METAP2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.